{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.94","groupDescription":"The trial was designed to concurrently provide 80% power for the detection of a 25% relative reduction in mortality hazard (hazard ratio .75) and 30% reduction in progression hazard (hazard ratio .70) for the addition of bevacizumab to temozolomide and radiation. To control for type I error in testing the co-primary endpoints, the significance criterion for OS was 0.023 (one-sided) and for PFS was 0.002 (one-sided).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","pValueComment":"To control for type I error in testing the co-primary endpoints, the significance criterion for OS was 0.023 (one-sided) and for PFS was 0.002 (one-sided).","paramType":"Cox Proportional Hazard","paramValue":"0.79","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"7.9","value":"7.3"},{"groupId":"OG001","lowerLimit":"10.0","upperLimit":"12.2","value":"10.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"description":"Progression-free survival was defined as time from randomization to date of progression, death, or last follow-up, and was estimated by the Kaplan-Meier method. Patients last known to be alive were censored at the date of last contact. This analysis was planned to occur when 390 deaths had been reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Temozolomide post-randomization,Radiation therapy post-randomization, placebo","id":"OG000","title":"Randomized Arm 1: TMZ+RT + Placebo"},{"description":"Temozolomide post-randomization, radiation therapy post-randomization, bevacizumab","id":"OG001","title":"Randomized Arm 2: TMZ+RT + Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"All eligible randomized patients","reportingStatus":"POSTED","timeFrame":"From randomization to date of progression, death, or last follow-up for progression-free survival. Analysis occurs after all 390 deaths have been reported.","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}